Philippe Ronga

500 total citations
13 papers, 251 citations indexed

About

Philippe Ronga is a scholar working on Oncology, Economics and Econometrics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Philippe Ronga has authored 13 papers receiving a total of 251 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Economics and Econometrics and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Philippe Ronga's work include Colorectal Cancer Treatments and Studies (11 papers), Economic and Financial Impacts of Cancer (6 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Philippe Ronga is often cited by papers focused on Colorectal Cancer Treatments and Studies (11 papers), Economic and Financial Impacts of Cancer (6 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Philippe Ronga collaborates with scholars based in Germany, Italy and Spain. Philippe Ronga's co-authors include Sebastian Stintzing, Zev A. Wainberg, Dan Aderka, Jesús García‐Foncillas, Yu Sunakawa, Clara Montagut, Julien Taı̈eb, Richard M. Goldberg, Daniele Santini and Salvatore Siena and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Frontiers in Oncology.

In The Last Decade

Philippe Ronga

13 papers receiving 247 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philippe Ronga Germany	6	180	79	52	50	41	13	251
Johan M. van Rooijen Netherlands	8	145 0.8×	58 0.7×	49 0.9×	37 0.7×	21 0.5×	16	224
M. D’Arcangelo Italy	12	200 1.1×	196 2.5×	79 1.5×	119 2.4×	41 1.0×	31	360
Chen‐Yang Huang Taiwan	11	180 1.0×	139 1.8×	40 0.8×	65 1.3×	24 0.6×	37	356
Carminia M. Della Corte Italy	7	139 0.8×	103 1.3×	71 1.4×	129 2.6×	37 0.9×	14	323
Soetkin Vlassak Germany	6	239 1.3×	127 1.6×	33 0.6×	64 1.3×	15 0.4×	20	330
Gennaro Palmiotti Italy	9	163 0.9×	105 1.3×	61 1.2×	74 1.5×	47 1.1×	22	332
Jesper Andreas Palshof Denmark	9	246 1.4×	134 1.7×	49 0.9×	99 2.0×	16 0.4×	16	361
Yiming Zhao China	10	131 0.7×	72 0.9×	64 1.2×	122 2.4×	39 1.0×	19	293
Francesca Sparano Italy	9	219 1.2×	103 1.3×	65 1.3×	113 2.3×	78 1.9×	19	369
Arsène‐Bienvenu Loembé United Kingdom	9	196 1.1×	100 1.3×	33 0.6×	168 3.4×	42 1.0×	15	377

Countries citing papers authored by Philippe Ronga

Since Specialization

Citations

This map shows the geographic impact of Philippe Ronga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Ronga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Ronga more than expected).

Fields of papers citing papers by Philippe Ronga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Ronga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Ronga. The network helps show where Philippe Ronga may publish in the future.

Co-authorship network of co-authors of Philippe Ronga

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe Ronga. A scholar is included among the top collaborators of Philippe Ronga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe Ronga. Philippe Ronga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Cremolini, Chiara, Clara Montagut, Philippe Ronga, et al.. (2023). Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer. Frontiers in Oncology. 12. 946850–946850. 13 indexed citations

Boutmy, Emmanuelle, et al.. (2021). Real-world healthcare resource utilization and costs of weekly versus every-2-week cetuximab in metastatic colorectal cancer. Journal of Comparative Effectiveness Research. 10(5). 353–364. 5 indexed citations

Stintzing, Sebastian, et al.. (2020). Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment ofRASwild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study. Journal of Medical Economics. 23(5). 448–455. 10 indexed citations

Batech, Michael, et al.. (2020). Overall survival of cetuximab administered every two weeks versus weekly in real-world data of U.S. patients with metastatic colorectal cancer.. Journal of Clinical Oncology. 38(4_suppl). 23–23. 2 indexed citations

Batech, Michael, et al.. (2020). Real-world costs of cetuximab + chemotherapy administered every two weeks versus weekly for treatment of metastatic colorectal cancer.. Journal of Clinical Oncology. 38(4_suppl). 22–22. 2 indexed citations

Lamy, François-Xavier, et al.. (2020). Comparative effectiveness of weekly versus every-2-weeks cetuximab in metastatic colorectal cancer in a US-insured population. Journal of Comparative Effectiveness Research. 9(16). 1117–1129. 4 indexed citations

García‐Foncillas, Jesús, Yu Sunakawa, Dan Aderka, et al.. (2019). Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors. Frontiers in Oncology. 9. 849–849. 133 indexed citations

Lamy, François-Xavier, et al.. (2019). Real-world study of cetuximab used every other week versus weekly in US patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 37(15_suppl). e15087–e15087. 3 indexed citations

Goldberg, Richard M., Clara Montagut, Zev A. Wainberg, et al.. (2018). Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. ESMO Open. 3(4). e000353–e000353. 42 indexed citations

10.

Kraemer, Matthias, et al.. (2017). A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies. Supportive Care in Cancer. 26(4). 1169–1179. 14 indexed citations

11.

Saunders, Mark, Carisa M. Cooney, Saifee Mullamitha, et al.. (2016). Performance assessment of blood based RAS mutation testing: Concordance of results obtained from prospectively collected samples. Annals of Oncology. 27. vi173–vi173. 1 indexed citations

12.

Köhne, C.-H., G.J. Poston, Gunnar Folprecht, et al.. (2016). FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study. European Journal of Surgical Oncology. 42(10). 1540–1547. 20 indexed citations

13.

Köhne, C.-H., Gunnar Folprecht, Fortunato Ciardiello, et al.. (2014). Folfiri Plus Cetuximab in Patients with Liver-Limited or Non-Liver-Limited Ras Wild-Type Metastatic Disease: a Sub-Group Analysis of the Crystal Study. Annals of Oncology. 25. iv184–iv184. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact